Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 2Non Small Cell Lung Cancer NSCLC 1Lung Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12durvalumab 12Trastuzumab 12Lenalidomide 12daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has announcements × tremelimumab × Clear all
NCT03043872 2026-04-22

CASPIAN

AstraZeneca

Phase 3 Active not recruiting
987 enrolled 42 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT03298451 2026-03-20

HIMALAYA

AstraZeneca

Phase 3 Active not recruiting
1,324 enrolled 31 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT03164616 2026-03-13

POSEIDON

AstraZeneca

Phase 3 Active not recruiting
1,186 enrolled 26 charts 1 FDA
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT03703297 2025-11-21

ADRIATIC

AstraZeneca

Phase 3 Active not recruiting
730 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡